Skip to main content

Table 3 Other secondary outcomes over 12 weeks

From: Diclofenac–hyaluronate conjugate (diclofenac etalhyaluronate) intra-articular injection for hip, ankle, shoulder, and elbow osteoarthritis: a randomized controlled trial

Joint Joint-specific questionnaires LSM change from baseline (95% CI)
DF − HA Placebo Difference
Hip N 46 44  
Patient global assessment score (mm)a −35.5 (−44.5 to −26.5) −25.7 (−35.7 to −15.6) −9.9 (− 17.9 to − 1.8)
Physician global assessment score (mm)a − 27.6 (−35.3 to −19.8) −23.8 (−32.3 to −15.2) −3.8 (−10.6 to 3.0)
SF-36 summary score    
MCS 4.5 (1.8 to 7.3) 4.6 (1.6 to 7.7) −0.1 (−2.6 to 2.4)
RCS 3.7 (−1.1 to 8.5) 1.0 (−4.3 to 6.2) 2.8 (−1.5 to 7.1)
PCS 4.9 (0.3 to 9.4) 0.8 (−4.3 to 5.8) 4.1 (0.0 to 8.3)
EQ-5D    
QOL score 0.13 (0.07 to 0.19) 0.06 (−0.00 to 0.13) 0.07 (0.02 to 0.12)
VAS score 17.4 (8.6 to 26.2) 11.0 (1.1 to 20.9) 6.4 (−1.8 to 14.6)
Ankle N 30 30  
Patient global assessment score (mm)a −21.7 (−29.9 to −13.4) −21.3 (−30.3 to −12.3) −0.3 (−10.4 to 9.7)
Physician global assessment score (mm)a −25.0 (−32.1 to −18.0) −24.2 (−32.1 to −16.3) −0.8 (−9.5 to 7.8)
SF-36 summary score    
MCS 3.7 (0.8 to 6.7) 2.8 (−0.3 to 5.9) 0.9 (−2.6 to 4.4)
RCS −5.4 (−10.8 to 0.0) −2.9 (−8.8 to 3.0) −2.5 (−9.0 to 4.0)
PCS −0.3 (−4.9 to 4.3) −2.6 (−7.4 to 2.1) 2.4 (−3.2 to 7.9)
EQ-5D    
QOL score 0.06 (0.01 to 0.12) 0.06 (−0.00 to 0.12) 0.00 (−0.06 to 0.07)
VAS score 1.6 (−5.4 to 8.6) 1.2 (−6.4 to 8.8) 0.4 (−8.0 to 8.9)
Shoulder N 45 45  
Patient global assessment score (mm)a −20.2 (−25.3 to −15.1) −20.1 (− 25.3 to −14.8) −0.1 (− 6.7 to 6.4)
Physician global assessment score (mm)a −20.5 (− 25.6 to − 15.4) −19.9 (− 25.2 to − 14.7) −0.5 (−7.1 to 6.0)
SF-36 summary score    
MCS 3.3 (0.9 to 5.6) 2.8 (0.4 to 5.2) 0.5 (−2.5 to 3.5)
RCS −1.4 (−4.9 to 2.2) −0.2 (−3.9 to 3.5) −1.2 (−5.7 to 3.3)
PCS 0.3 (−2.6 to 3.2) 2.3 (−0.7 to 5.3) −2.0 (−5.7 to 1.7)
EQ-5D    
QOL score 0.06 (0.02 to 0.09) 0.08 (0.05 to 0.12) −0.03 (−0.07 to 0.02)
VAS score 5.0 (−0.3 to 10.4) 8.1 (2.7 to 13.6) −3.1 (−9.8 to 3.7)
Elbow N 25 25  
Patient global assessment score (mm)a −26.2 (−37.5 to −14.9) −29.9 (−41.1 to −18.8) 3.7 (−7.6 to 15.0)
Physician global assessment score (mm)a −20.1 (−30.1 to −10.1) −25.8 (−35.8 to −15.9) 5.7 (−4.1 to 15.6)
SF-36 summary score    
MCS 1.4 (−2.9 to 5.8) 3.7 (−0.6 to 8.0) −2.3 (−6.6 to 2.0)
RCS −5.6 (−10.5 to −0.8) −1.9 (−6.7 to 3.0) −3.8 (−8.6 to 1.1)
PCS 4.6 (−0.4 to 9.6) 1.0 (−3.8 to 5.9) 3.6 (−1.4 to 8.6)
EQ-5D    
QOL score 0.02 (−0.05 to 0.09) 0.06 (−0.01 to 0.13) −0.04 (− 0.11 to 0.04)
VAS score 1.8 (−6.5 to 10.2) 3.9 (−4.4 to 12.3) −2.1 (−10.6 to 6.4)
  1. LSM least-squares means, CI confidence interval, DF-HA diclofenac etalhyaluronate, SF-36 Medical Outcomes Study 36-Item Short Form Health Survey, MCS mental component summary, RCS role/social component summary, PCS physical component summary, EQ-5D EuroQol 5 Dimensions, QOL quality of life, VAS visual analog scale
  2. aAverage of 7 days prior to Week 0 by the 0–100 mm visual analog scale for pain intensity: 0 mm indicates no pain, and 100 mm indicates the worst pain